Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

2cureX

3.29

 

SEK

 

+35.95 %

Less than 1K followers

2CUREX

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Ownership
Compare
+35.95%
+358.22%
+789.19%
+679.62%
+600%
+765.79%
-72.49%
-74.89%
-56.75%

2cureX is a Danish-based biotech company with subsidiary in Hamburg, Germany. The company has made a special sensitivity test, IndiTreat, for oncology clinics that is focused on improving the outcome for cancer patients by improving the efficiency of the individual cancer treatment. IndiTreat uses a biopsy from the individual cancer patient to measure and predict the likely outcome of different available treatments, thereby assisting oncologists to choose the most effective treatment for the individual patient.

Read more
Market cap
82.59M SEK
Turnover
2.15M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
26/6
2025

General meeting '25

21/8
2025

Interim report Q2'25

26/2
2026

Annual report '25

All
Press releases
3rd party
ShowingAll content types
Regulatory press release5/30/2025, 11:30 AM

KALLELSE TILL ÅRSSTÄMMA I 2CUREX AB (publ).

2cureX
Regulatory press release5/30/2025, 11:30 AM

NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ).

2cureX
Regulatory press release5/29/2025, 3:30 PM

PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (PUBL)

2cureX

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/29/2025, 3:30 PM

RELEASE OF THE 2CUREX AB (PUBL) ANNUAL REPORT

2cureX
Regulatory press release5/22/2025, 7:15 AM

2cureX appoints Mangold Fondkommission AB as new Certified Adviser

2cureX
Press release5/20/2025, 8:00 AM

2cureX Conducts First Direct-to-Patient IndiTreat® Test Under “Operation Twin Code” Strategy

2cureX
Regulatory press release5/15/2025, 3:20 PM

2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap

2cureX
Press release4/14/2025, 10:00 AM

EARLY NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ)

2cureX
Regulatory press release2/27/2025, 12:00 PM

2cureX publishes interim report for the second half year of 2024

2cureX
Press release1/20/2025, 3:00 PM

2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE

2cureX
Regulatory press release1/10/2025, 3:00 PM

Correction: 2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE

2cureX
Regulatory press release1/10/2025, 1:00 PM

2CUREX APPOINTS MANGOLD CORPORATE FINANCE TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE

2cureX
Regulatory press release12/18/2024, 6:15 PM

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

2cureX
Regulatory press release12/18/2024, 6:15 PM

BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)

2cureX
Regulatory press release12/16/2024, 12:00 PM

2cureX AB Announces the Appointment of Dan Honeywell as CEO, Ushering in a New Era of commercial expansion of breakthrough precision oncology products

2cureX
Regulatory press release11/29/2024, 2:00 PM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB

2cureX
Regulatory press release11/29/2024, 2:00 PM

NOTICE OF EXTRA GENERAL MEETING IN 2CUREX AB

2cureX
Regulatory press release9/24/2024, 5:45 PM

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

2cureX
Regulatory press release9/24/2024, 5:45 PM

BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)

2cureX
Press release9/9/2024, 10:30 AM

Invitation to 2cureX Webcast with Q&A on 24 September 2024

2cureX
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team